Jeffrey Adam Engelman MD, PhD

Dr. Engelman is the principal investigator of his own laboratory at the Massachusetts General Hospital (MGH) Cancer Center, the director of thoracic oncology at MGH and the director of molecular therapeutics at the MGH Cancer Center. He received his B.A. in chemistry from Northwestern University and his M.D. and Ph.D. degrees from the Albert Einstein College of Medicine. Dr. Engelman completed his medical residency in internal medicine at Brigham and Women’s Hospital and his fellowship in hematology and oncology at the Dana-Farber Cancer Institute/MGH combined program. He joined the Harvard Medical School faculty and MGH in 2005. The research goal of his laboratory is to advance targeted therapies to benefit patients with cancer. His research focuses on understanding the biological underpinnings of sensitivity and resistance to specific kinase inhibitor targeted therapies in cancers with specific genetic abnormalities. In particular, his laboratory focuses on the regulation of key signaling networks that regulate cancer cell growth and survival. In his role as the director of thoracic oncology at MGH, he directs the research program of the thoracic oncology team. This program integrates laboratory studies, clinical trials, and comprehensive molecular analyses of cancers to pioneer individualized therapies. He has established a well-developed translational infrastructure that has culminated in a seamless bench-to-bedside connection with each activity informing the other.